Autolus results for the third quarter of 2026 are scheduled for release before US markets open on November 10. The biopharmaceutical company also plans to publish operational highlights and host a management call that morning.

How to follow Autolus results

Management will discuss the financial results and provide a general business update on a conference call and webcast at 8:30 a.m. EST, or 1:30 p.m. GMT, on November 10.

Telephone participants must pre-register to receive the dial-in numbers and personal PIN required to join. A simultaneous audio webcast and replay will be accessible in the events section of the company’s website.

Autolus announced the schedule on October 26 but did not disclose its quarterly financial figures.

About the T cell therapy company

Autolus develops, manufactures and delivers T cell therapies and candidates for cancer and autoimmune diseases. The commercial-stage company has a marketed therapy and a pipeline of candidates for blood cancers, solid tumors and autoimmune diseases.

Its shares trade on Nasdaq under the ticker AUTL.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.